The research-grade biosimilar is an investigational human monoclonal antibody that targets angiopoietin-like 3 inhibitor (ANGPTL3). ANGPTL3 is primarily expressed in the liver and it inhibits LPL activity and endothelial lipase activity. This prevents the clearance of lipids and raises the concentration of triglycerides and LDL-C in the blood. The antibody binds with high affinity and specificity to ANGPTL3 and reverses the inhibitory action on LPL, thus promoting the clearance of LDL-C from the blood. The original drug was awarded breakthrough therapy designation by the FDA to treat patients suffering from homozygous familial hypercholesterolemia (HoFH).
In PBS, pH 7.5